BioAtla Building China Antibody Ops As It Eyes IPO
This article was originally published in PharmAsia News
BioAtla has entered a strategic and option agreement with Pfizer to develop a new class of antibody therapeutics, and plans to continue working with BioDuro as part of its R&D plans and efforts in China, which include a manufacturing site in Hefei. Meanwhile, BioAtla is also eyeing a possible IPO on Nasdaq next year.
Register for our free email digests: